Cell Reports, Volume 28

# **Supplemental Information**

# Spinal Neuropeptide Y1 Receptor-Expressing

### **Neurons Form an Essential Excitatory**

## Pathway for Mechanical Itch

David Acton, Xiangyu Ren, Stefania Di Costanzo, Antoine Dalet, Steeve Bourane, Ilaria Bertocchi, Carola Eva, and Martyn Goulding

### **Supplemental Information**

### Spinal NPY1R+ Neurons form an Essential Excitatory Pathway for Mechanical Itch

David Acton, Xiangyu Ren, Stefania Di Costanzo, Antoine Dalet, Steeve Bourane, Illarai Bertocchi, Carola Eva, and Martyn Goulding



### Figure S1 related to Figure 1. Characterization of *Y1::EGFP* expression.

(A) Sections from the lumbar spinal cord of a P42  $Y1^{Cre}$ ; Y1::EGFP;  $Ai14^{lsl-tdTom}$  mouse showing overlapping expression of tdTomato and eGFP. Scale bar: 100 µm. (B) Summary of tdTomato and eGFP co-expression (n = 4 mice). (C) Comparison of Y1-tdTomato and Y1-eGFP expression by lamina (n = 6-9 mice). Data: mean ± SEM.



Figure S2 related to Figure 1. Co-expression of markers of dorsal horn cell populations with Y1<sup>Cre</sup>.

(A-D) Sections of lumbar spinal cords showing co-expression of  $YI^{Cre}$  with markers of dorsal horn excitatory neurons: cMaf co-expression was assessed by antibody staining in lumbar spinal cord sections from P42  $YI^{Cre}$ ;  $Ai14^{lsl-tdTom}$  mice (A). RAR-related orphan receptor alpha (ROR $\alpha$ ) expression was assessed by antibody labelling in P10  $YI^{Cre}$ ;  $Ai14^{lsl-tdTom}$  mice (B). Co-expression of  $YI^{Cre}$  with gastrin releasing peptide (GRP) and antibody-labeled gastrin-releasing peptide receptor (GRPR) was assessed in P42  $YI^{Cre}$ ;  $Ai14^{lsl-tdTom}$ ; GRP::eGFP mice (C). Neurokinin-1 receptor (NK1R) co-expression was assessed by antibody staining in lumbar spinal cord sections from P42  $YI^{Cre}$ ;  $Ai14^{lsl-tdTom}$  mice; an antibody against the pan-neuronal marker NeuN was employed to facilitate identification of Y1-tdTomato<sup>-</sup> cells. Arrowheads: Y1-tdTomato<sup>-</sup>/NK1R<sup>+</sup> neurons (D). (E) Somatostatin (Sst) coexpression was assessed by comparing Y1<sup>+</sup>/Sst<sup>+</sup> neurons in P42  $YI^{Cre}$ ;  $Sst^{FlpO}$ ;  $Ai65^{ds-tdTom}$  mice. (F and G) Quantification of the data exemplified in panels A-E: the proportions of Y1<sup>-Cre</sup> neurons co-expressing markers of other neuronal populations (F) and of those other populations co-expressing tdTomato (G). (H and I) tdTomato did not colocalize with antibody-labeled GFAP (H) or S100ß (I), markers of glia. n = 3-5 mice for each condition. Scale bars: 100 µm. Data: mean ± SEM.

#### Y1<sup>Cre</sup>; R26<sup>IsI-TVA</sup>; ∆G Rabies-dsRed



### Figure S3 related to Figure 1. Morphological analysis of Y1<sup>Cre</sup> neurons.

(A-F) Examples of laminae I-IV Y1<sup>Cre</sup> neuron morphologies (red) in sagittal sections from the lumbar spinal cord of P15 *Y1<sup>Cre</sup>*; *R26<sup>ls1-TVA</sup>* mice injected with EnvA  $\Delta$ G dsRed-rabies virus at P10. (G) Quantification of Y1<sup>Cre</sup> neuronal morphologies in laminae I-IV. *n* = 53 cells from 5 mice. Scale Bars: 50 µm.



#### Figure S4 related to Figure 3. Ablation efficiency in NPY::Cre IN phenotype-recovery experiment.

(A-C) Transverse sections through the lumbar spinal cords of P49 mice treated with saline (control, left) or DT (ablated, right): *NPY::Cre; Lbx1<sup>FlpO</sup>; Tau<sup>ds-DTR</sup>; Ai65<sup>ds-tdTom</sup>*(A), *Y1<sup>Cre</sup>; NPY::Cre; Lbx1<sup>FlpO</sup>; Tau<sup>ds-DTR</sup>; Ai65<sup>ds-tdTom</sup>*(B), *Sst<sup>Cre</sup>; NPY::Cre; Lbx1<sup>FlpO</sup>; Tau<sup>ds-DTR</sup>; Ai65<sup>ds-tdTom</sup>*(C). (D) Summary of cell numbers for each condition. The ablation efficiency, assessed as percentage reduction in cell number, did not differ between genotypes (one-way ANOVA, p > 0.5). (E) Percentage reduction of NeuN<sup>+</sup> neurons in laminae I-IV for each DT-treated phenotype. n = 3sections from 4 mice per condition. Scale bars: 100 µm. \*\*\*p < 0.001. Data: mean ± SEM.



Figure S5 related to Figure 3. Sst<sup>Cre</sup> neurons do not determine sensitivity to mechanical itch.

(A) Spontaneous scratching is unchanged in mice 1 week after ablation of dorsal horn Sst<sup>Cre</sup> (*Sst<sup>Cre</sup>*; *Lbx1<sup>FlpO</sup>*; *Tau<sup>ds-DTR</sup>*; *Ai65<sup>ds-tdTom</sup>*; n = 8) or Y1<sup>Cre</sup> neurons (*Y1<sup>Cre</sup>*; *Lbx1<sup>FlpO</sup>*; *Tau<sup>ds-DTR</sup>*; *Ai65<sup>ds-tdTom</sup>*, n = 10) compared with DT-treated controls lacking FlpO-dependent DT-receptor expression (*Sst<sup>Cre</sup>*; *Tau<sup>ds-DTR</sup>*; *Ai65<sup>ds-tdTom</sup>*, n = 10; *Y1<sup>Cre</sup>*; *Tau<sup>ds-DTR</sup>*; *Ai65<sup>ds-tdTom</sup>*, n = 7). (B) Scratching responses to stimulation of the nape by a 0.16 g von Frey hair are unchanged when Sst<sup>+</sup> neurons are ablated in *Sst<sup>Cre</sup>*; *Lbx1<sup>FlpO</sup>*; *Tau<sup>ds-DTR</sup>*; *Ai65<sup>ds-tdTom</sup>* mice treated with DT (n = 9) compared with saline-treated controls (n = 7). (C) Sections of lumbar spinal cords from P49 *Sst<sup>Cre</sup>*; *Lbx1<sup>FlpO</sup>*; *Tau<sup>ds-DTR</sup>*; *Ai65<sup>ds-tdTom</sup>* mice treated with saline (control) or DT (ablated). (D) Summary of ablation efficiency (control, n = 4 mice; ablated, n = 5; 3 sections per cord). Scale bars: 100 µm. \*\*\*p < 0.001. Data: mean ± SEM.



#### Figure S6 related to Figure 3. Efficiency of cell ablation.

(A) Sections of lumbar spinal cords from P49  $Y1^{Cre}$ ;  $Lbx1^{FlpO}$ ;  $Tau^{ds-DTR}$ ;  $Ai65^{ds-tdTom}$  mice treated with saline (control; left) or DT (ablated; right). Scale bar: 100 µm. (**B**) Summary of Y1<sup>Cre</sup> neuron ablation efficiency (control, 6 cords; ablated, 7 cords; 3 sections per cord). (**C**) Sections from P42 wild type mice showing loss of GRPR immunoreactivity in the superficial dorsal horn at the cervical level 2 weeks after treatment with control SAP (left panel) or BOM-SAP (right panel) to ablate GRPR<sup>+</sup> neurons. Scale bar: 20 µm. (**D**) Summary of GRPR<sup>+</sup> neuron ablation efficiency (control, n = 3 mice; ablated, n = 3; 3 sections per cord). (**E**) Chloroquine-induced scratching is reduced in wild type mice 2 weeks following treatment with BOM-SAP (n = 6; controls, n = 8). (**F**) Sections from P42 wild type mice showing loss of NK1R immunoreactivity in the superficial dorsal horn at the cervical level 2 weeks after treatment with control SAP (left panel) or with SSP-SAP (right panel) to ablate NK1R<sup>+</sup> neurons. Scale bar: 10  $\mu$ m. (G) Summary of NK1R<sup>+</sup> neuron ablation efficiency (control, *n* = 3 mice; ablated, *n* = 3; 3 sections per cord). (H) Chloroquine-induced scratching is reduced in wild type mice 2 weeks following treatment with SSP-SAP (*n* = 7; controls, *n* = 10). \**p* < 0.05, \*\*\**p* < 0.001. Data: mean ± SEM.



Figure S7 related to Figures 6 and 7. Y1 receptors modulate mechanical itch.

(A and B) I.t. injection of BIBP 3226 (5 µg in 10 µl) increases both spontaneous (A; n = 10; controls, n = 10) and evoked (B; n = 9; controls, n = 9) scratching. (C) Disruption of NPY-Y1 signaling increases spontaneous scratching in global NPY KO mice (n = 8; littermate control, n = 8), or following i.p. injection of wild type mice with the Y1 antagonist BMS 193885 (1 mg kg<sup>-1</sup>, n = 11; vehicle, n = 11). (D) Spontaneous scratching in *NPY::Cre; Lbx1<sup>FlpO</sup>; Tau<sup>ds-DTR</sup>; Ai65<sup>ds-tdTom</sup>* mice 1 week after DT treatment is reduced by i.t. injection of the selective Y1 agonist [Leu<sup>31</sup>, Pro<sup>34</sup>]-NPY (1.5 ng in 10 µl; n = 8) compared with vehicle. A two-tailed, paired t-test was used to assess statistical difference. (E) Evoked scratching is reduced when mice are injected with NPY (100 µg kg<sup>-1</sup>, i.p., n = 9; vehicle, n =10). (F) Scratching in response to nape stimulation is reduced following i.t. injection of [Leu<sup>31</sup>, Pro<sup>34</sup>]-NPY (n = 6; controls, n = 8). \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001. Data: mean ± SEM.